A likely cause of nomifensine toxicity is the aromatic amine group, as compounds containing this chemical substructure are notorious for producing toxic metabolites.
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Hydrocodone | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Magnesium sulfate | The therapeutic efficacy of Nomifensine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Nomifensine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Mirtazapine | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Orphenadrine | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Pramipexole | Nomifensine may increase the sedative activities of Pramipexole. |
| Ropinirole | Nomifensine may increase the sedative activities of Ropinirole. |
| Rotigotine | Nomifensine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Nomifensine. |
| Sodium oxybate | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Thalidomide | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Nomifensine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Nomifensine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Nomifensine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Nomifensine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Nomifensine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Nomifensine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Nomifensine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Nomifensine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Nomifensine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Nomifensine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Nomifensine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Nomifensine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Nomifensine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Nomifensine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Nomifensine is combined with (S)-Warfarin. |
| Ethanol | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Nomifensine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Nomifensine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Nomifensine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Nomifensine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Nomifensine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Nomifensine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Nomifensine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Nomifensine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Nomifensine is combined with Alaproclate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Nomifensine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Nomifensine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Nomifensine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Nomifensine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Nomifensine. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Nomifensine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Nomifensine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Nomifensine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Nomifensine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Nomifensine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Nomifensine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Nomifensine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Nomifensine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Nomifensine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Nomifensine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Nomifensine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Nomifensine. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Nomifensine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Nomifensine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Nomifensine. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Nomifensine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Nomifensine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Nomifensine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Nomifensine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Nomifensine. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Nomifensine. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nomifensine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Nomifensine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Nomifensine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Nomifensine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Nomifensine. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Nomifensine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Nomifensine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Nomifensine. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Nomifensine. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Nomifensine. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Nomifensine. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Nomifensine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Nomifensine. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Nomifensine. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Nomifensine. |